{Reference Type}: Journal Article
{Title}: Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients.
{Author}: Zhao W;Liu Y;Zhang M;Cui Z;Qu Z;Li Y;Wan M;Wang W;Chen Y;Shi L;Li J;Ye F;
{Journal}: Front Med (Lausanne)
{Volume}: 11
{Issue}: 0
{Year}: 2024
{Factor}: 5.058
{DOI}: 10.3389/fmed.2024.1399665
{Abstract}: <B>UNASSIGNED: </B>This study was aimed at investigating the dynamics of lipids and the effect of TAF on the lipid profile of patients including fatty liver disease in CHB patients.<BR><B>UNASSIGNED: </B>The data of TC, LDL-c, HDL-c, TG, and TC/HDL ratio were collected at baseline, 24 weeks, 48 weeks, 72 weeks, and 96 weeks. CHB patients with fatty liver at baseline were further analyzed in a subgroup.<BR><B>UNASSIGNED: </B>A total of 137 CHB patients treated with TAF were enrolled in this study. During 96 weeks of TAF treatment, there was no significant change in TC, LDL-c, HDL-c, and TG level (P > 0.05). The TC/HDL-c ratio was increased with no significant change (+0.24, P > 0.05). In CHB patients with fatty liver (n = 48), TC, LDL-c, and TC/HDL-c ratio increased gradually during TAF treatment, TG levels increased to 146.63 mg/dL at 48 weeks (P = 0.057) and then decreased, but there was still no significant change compared with the baseline level by 96 weeks (P > 0.05).<BR><B>UNASSIGNED: </B>TAF treatment had a low effect on the lipid profile of CHB patients over the course of 96 weeks, and it was safe even in patients with fatty liver.<BR><B>UNASSIGNED: </B>[https://www.chictr.org.cn/showproj.html?proj=65123], identifier [ChiCTR2000041005].